BeOne Medicines Ltd (HK:6160)
:6160
Want to see HK:6160 full AI Analyst Report?
Total Valuation
BeOne Medicines Ltd has a market cap or net worth of HK$273.94B. The enterprise value is HK$28.99B.
Market CapHK$273.94B
Enterprise ValueHK$28.99B
Share Statistics
BeOne Medicines Ltd has 1,426,363,900 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,426,363,900
Owned by Insiders―
Owned by Institutions<0.01%
Financial Efficiency
BeOne Medicines Ltd’s return on equity (ROE) is 0.07 and return on invested capital (ROIC) is 4.76%.
Return on Equity (ROE)0.07
Return on Assets (ROA)0.03
Return on Invested Capital (ROIC)4.76%
Return on Capital Employed (ROCE)0.07
Revenue Per Employee486.45K
Profits Per Employee26.12K
Employee Count11,000
Asset Turnover0.65
Inventory Turnover1.30
Valuation Ratios
The current PE Ratio of BeOne Medicines Ltd is 34.8. BeOne Medicines Ltd’s PEG ratio is -0.80.
PE Ratio34.8
PS Ratio6.10
PB Ratio7.49
Price to Fair Value7.49
Price to FCF34.63
Price to Operating Cash Flow26.35
PEG Ratio-0.80
Income Statement
In the last 12 months, BeOne Medicines Ltd had revenue of 5.35B and earned 287.36M in profits. Earnings per share was 0.20.
Revenue5.35B
Gross Profit4.56B
Operating Income447.80M
Pretax Income417.47M
Net Income287.36M
EBITDA589.69M
Earnings Per Share (EPS)0.20
Cash Flow
In the last 12 months, operating cash flow was 1.29B and capital expenditures -191.17M, giving a free cash flow of 1.10B billion.
Operating Cash Flow1.29B
Free Cash Flow1.10B
Free Cash Flow per Share0.77
Dividends & Yields
BeOne Medicines Ltd pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.93
52-Week Price Change28.66%
50-Day Moving Average180.53
200-Day Moving Average191.91
Relative Strength Index (RSI)52.19
Average Volume (3m)5.08M
Important Dates
BeOne Medicines Ltd upcoming earnings date is Aug 21, 2026, TBA (Confirmed).
Last Earnings DateMay 6, 2026
Next Earnings DateAug 21, 2026
Ex-Dividend Date―
Financial Position
BeOne Medicines Ltd as a current ratio of 3.41, with Debt / Equity ratio of 43.13%
Current Ratio3.41
Quick Ratio3.08
Debt to Market Cap0.06
Net Debt to EBITDA-5.93
Interest Coverage Ratio7.68
Taxes
In the past 12 months, BeOne Medicines Ltd has paid 130.11M in taxes.
Income Tax130.11M
Effective Tax Rate0.31
Enterprise Valuation
BeOne Medicines Ltd EV to EBITDA ratio is 49.45, with an EV/FCF ratio of 30.92.
EV to Sales5.45
EV to EBITDA49.45
EV to Free Cash Flow30.92
EV to Operating Cash Flow25.82
Balance Sheet
BeOne Medicines Ltd has HK$4.83B in cash and marketable securities with HK$2.05B in debt, giving a net cash position of HK$2.78B billion.
Cash & Marketable SecuritiesHK$4.83B
Total DebtHK$2.05B
Net CashHK$2.78B
Net Cash Per ShareHK$1.95
Tangible Book Value Per ShareHK$3.05
Margins
Gross margin is 87.16%, with operating margin of 8.37%, and net profit margin of 5.37%.
Gross Margin87.16%
Operating Margin8.37%
Pretax Margin7.80%
Net Profit Margin5.37%
EBITDA Margin11.02%
EBIT Margin8.37%
Analyst Forecast
The average price target for BeOne Medicines Ltd is HK$253.58, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price TargetHK$253.58
Price Target Upside31.25% Upside
Analyst ConsensusStrong Buy
Analyst Count14
Revenue Growth Forecast37.65%
EPS Growth Forecast―